Skip to main content

Table 1. Characteristics of study subjects included in immunohistochemical analysis

From: NHLRC2 expression is increased in idiopathic pulmonary fibrosis

Parameters

IPF (n = 50)

Control (n = 10)

Tissue sample histology, n (%)

Normal

–

10 (100)

UIP

47 (94)

–

UIP and DAD

3 (6)

–

Two separate lung tissue samples—Surgical lung biopsy and autopsy lung tissue specimen, n (%)

UIP in biopsy and UIP with DAD in autopsy

6 (12)

–

UIP with DAD in both biopsy and autopsy specimens

2 (4)

–

Age years, mean (SD)

62.3 (7.9)

70.5 (6.4)

Gender, n (%)

  

Male

37 (74)

1 (10)

Female

13 (26)

9 (90)

Smoking status, n (%)a

  

Never-smoker

17 (38)

9 (90)

Ex-smoker

20 (44)

1 (10)

Current smoker

8 (18)

0 (0)

Pack-years of ever-smokers, median (IQR)b

25.0 (19.5–37.0)

7

FVC%, mean (SD)c

73.8 (15.5)

100.8 (17.5)

FEV1%, mean (SD)c

78.4 (16.7)

99.3 (19.3)

DLCO%, median (IQR)d

53.0 (45.0–62.1)

87.8 (76.4–111.0)

Follow up time, months, median (IQR)e

41.3 (15.1–73.8)

–

Episode of AE during follow-up, n (%)

22 (44)

–

Diseased or transplanted, n (%)

39 (78)

–

Transplanted, n (%)

4 (8.0)

–

  1. The values were from the time of surgical lung biopsy (IPF). For follow-up time, death or lung transplantation was used as an endpoint event. Follow-up time for patients having no endpoints was defined as the time between biopsy date and May 11, 2021. Non-smoking patients operated for lung cancer were used as controls
  2. AE acute exacerbation, DAD diffuse alveolar damage, DLCO% percent predicted diffuse capacity for carbon monoxide, FEV1% percent predicted forced expiratory volume at one second, FVC% percent predicted forced vital capacity, IQR interquartile range, n number, SD standard deviation, UIP usual interstitial pneumonia
  3. aIPF n = 45
  4. bIPF n = 25
  5. cIPF n = 42, control n = 9
  6. dIPF n = 41, control n = 8
  7. eIPF n = 49